 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
10th January 2007
F2G
Ltd Announces Appointment of new Chief Scientific Officer
Manchester, England, 10th January 2007 - F2G Limited, specialists
in research and development of new treatments for serious fungal infections
in man, is pleased to announce the appointment of Dr Lloyd Payne as
Chief Scientific Officer.
This appointment signifies a promotion for Dr Payne who joined F2G Ltd
as Vice President of Research and Development in April 2006. He had
previously held senior scientific and management positions within Cambridge
Discovery Chemistry Ltd, NCE Discovery Ltd and more recently at Millennium
Pharmaceuticals where he was responsible for the leadership of multidisciplinary
drug discovery project teams based in the UK and US.
Dr Payne takes over the CSO position from Dr Jeff Edwards who is assuming
the Chairmanship of the Board Science Committee.
Shane Kelly, Chief Executive of F2G, stated "We have been very
impressed with the positive impact Lloyd has had on our scientific progress
since he joined the Company. I personally wish Lloyd and Jeff every
success in their new roles and thank them for their efforts to date".
Lloyd Payne commented "F2G is focused on the development of novel
therapies for the treatment of life-threatening fungal infections and
has assembled an impressive range of capabilities in fungal biology
and drug discovery. This is an exciting stage of the Company's evolution
and I look forward to working with the team to enable continued progression
of current programs towards the market."
F2G's
technologies focus on the development of new and innovative drug treatments
for systemic fungal infections in man. This market is currently estimated
at over five and a half billion dollars annually and is growing at approximately
20% per year. In addition, there is new evidence suggesting a correlation
between fungal infections and allergic conditions (including asthma).
If proven, this would add significantly to the growth of the total addressable
market. F2G has developed unique capabilities in the field including
proprietary genomic targets, target validation, drug discovery and drug
development. The Company has also amassed unique expertise in the fields
of clinical need and corporate and business development specific to
the field.
For
more information visit www.f2g.com
Contact:
Shane Kelly
Chief Executive Officer
F2G Ltd
Tel: (+44) 0161 785 1270
Fax: (+44) 0161 785 1273
Email: shanekelly@f2g.com
Tel +44 (0)161 785 1270 Fax +44 (0)161 785 1273 Email contact@f2g.com